Treatment
Blinatumomab clinical trials
We’re tracking 56 recruiting studies that include Blinatumomab, each written for real people, not researchers, below.
Recruiting studies
- NCT05827549RecruitingPhase 2
Blinatumomab for relapsed ALL, matched by risk group
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
DaeguAges 1–22 - NCT06789107RecruitingPhase 1
Blinatumomab for severe childhood lupus
This trial tests a drug called blinatumomab for children with active lupus that hasn't improved with standard treatments. It aims to see if this immunotherapy can help calm the immune system and reduce lupus activity.
Hangzhou, ZhejiangAges 5 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Birmingham, AlabamaAges 1–30 - NCT04746209RecruitingPhase 2
Blinatumomab after transplant for high-risk B-ALL patients
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
Milwaukee, WisconsinAges Up to 25 years - NCT06339775RecruitingPhase 4
Blinatumomab for leukemia relapse after a stem cell transplant
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
Zhenzhou, HenanAges Up to 65 years - NCT06250959RecruitingPhase 2
Comparing a new drug to standard chemo for B-ALL
This trial tests if a new drug, RDC-Blinatumomab, works better than the usual chemotherapy (hyperCVAD) for people with a type of leukemia called Ph-negative B-ALL. It is for newly diagnosed patients who haven't had other treatments yet.
Suzhou, JiangsuAges 15–65 - NCT06554626RecruitingPhase 2
Study of blinatumomab and venetoclax followed by inotuzumab for B-ALL
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
Hangzhou, ZhejiangAges 40 years+ - NCT06607419RecruitingPhase 2/Phase 3
Blinatumomab for leftover leukemia in children with B-ALL
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
Hefei, AnhuiAges 1 month–18 years - NCT07677878RecruitingPhase 1
Blinatumomab and low-dose DLI after transplant for B-ALL
This trial tests adding a drug called blinatumomab plus a low-dose donor lymphocyte infusion (DLI) as maintenance therapy after stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It aims to reduce the chance of the cancer coming back.
BeijingAges 18–70 - NCT06393985RecruitingPhase 2
Maintenance therapy after stem cell transplant for B-ALL
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
Suzhou, JiangsuAges 18–65 - NCT06742515RecruitingPhase 2
Blinatumomab with lower-dose chemo for B-ALL
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
Hangzhou, ZhejiangAges 15–59 - NCT06886074RecruitingPhase 2
Short blinatumomab to clear leftover B-ALL cells
This trial tests if a shorter course of blinatumomab can remove minimal residual disease (MRD) — tiny traces of leukemia not seen under a microscope — in people with B-cell acute lymphoblastic leukemia after initial treatment.
Monterrey, Nuevo LeónAges 16–60 - NCT07222579RecruitingPhase 2
Study of blinatumomab injection for a rare leukemia type
This trial tests a new way to give blinatumomab (a drug that helps your immune system fight cancer) as a shot under the skin for a rare leukemia called MPAL. It includes three different groups of patients depending on their treatment history.
Morgantown, West VirginiaAges 18 years+ - NCT06061094RecruitingPhase 2
Ph+ ALL chemo with targeted pills and transplant
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
AachenAges 18–65 - NCT07133997RecruitingPhase 1
Combination therapy for relapsed CD19+ B-cell leukemia
This trial tests a new combination of three drugs for patients with relapsed or treatment-resistant CD19-positive B-cell acute lymphoblastic leukemia. It aims to see if adding the drugs venetoclax and asparaginase to blinatumomab can improve outcomes.
Duarte, CaliforniaAges 12–55 - NCT07052370RecruitingPhase 1
New stem cell transplant for children with high-risk blood cancer
This trial tests a special stem cell transplant from a half-matched family donor, designed to reduce rejection and infection risk. It may include a targeted drug (blinatumomab) to help kill remaining cancer cells.
Memphis, TennesseeAges Up to 21 years - NCT07003737Recruiting
Blinatumomab before stem cell transplant for high-risk B-ALL
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
Hangzhou, ZhejiangAges 18–65 - NCT06985485RecruitingPhase 2
Immunotherapy for older or frail B-ALL patients
This trial tests a full course of immunotherapy (drugs that help your immune system fight cancer) instead of intensive chemotherapy for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older or cannot tolerate strong chemo. It aims to offer an effective, less toxic option.
Suzhou, JiangsuAges 15 years+ - NCT06860269RecruitingPhase 2/Phase 3
New immune therapy and stem cell transplant for acute lymphoblastic leukemia
This study tests adding new immunotherapy drugs and possibly a stem cell transplant to the first treatment for adults with acute lymphoblastic leukemia (ALL). The goal is to see if these approaches help people live longer without the cancer coming back.
ParisAges 18–65 - NCT06764238RecruitingPhase 2/Phase 3
Treatment study for children with new B-cell ALL (intermediate/high risk)
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
Hefei, AnhuiAges 1 month–18 years - NCT06607991RecruitingPhase 1
Blinatumomab for children with steroid-resistant nephrotic syndrome
This trial tests a drug called blinatumomab for children with a kidney condition that doesn't respond to standard treatments. It aims to see if it can help when other drugs have failed or caused side effects.
Hangzhou, ZhejiangAges 2–17 - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
Scottsdale, ArizonaAges 18–75 - NCT06507514RecruitingPhase 1
Blinatumomab with stem cell transplant for B-ALL
This trial tests a treatment plan that uses blinatumomab (a drug that helps your immune system attack leukemia cells) combined with your own stem cell transplant. It is for people with B-ALL who cannot or choose not to have a transplant from another person.
Suzhou, JiangsuAges 15–65 - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Birmingham, AlabamaAges Up to 12 months
What Blinatumomab is being studied for
Conditions with recruiting Blinatumomab studies.
Common questions
- Are there clinical trials studying Blinatumomab?
- Yes. Clin2 currently lists 56 recruiting studies that include Blinatumomab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Blinatumomab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Blinatumomab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Blinatumomab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.